Literature DB >> 16695270

HEMODYNAMIC ALTERATIONS IN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS DURING THE PYROGENIC REACTION.

S E Bradley1, H Chasis, W Goldring, H W Smith.   

Abstract

Entities:  

Year:  1945        PMID: 16695270      PMCID: PMC435512          DOI: 10.1172/JCI101660

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  7 in total

1.  THE MEASUREMENT OF THE TUBULAR EXCRETORY MASS, EFFECTIVE BLOOD FLOW AND FILTRATION RATE IN THE NORMAL HUMAN KIDNEY.

Authors:  H W Smith; W Goldring; H Chasis
Journal:  J Clin Invest       Date:  1938-05       Impact factor: 14.808

2.  REDUCTION OF BLOOD PRESSURE ASSOCIATED WITH THE PYROGENIC REACTION IN HYPERTENSIVE SUBJECTS.

Authors:  H Chasis; W Goldring; H W Smith
Journal:  J Clin Invest       Date:  1942-07       Impact factor: 14.808

3.  BALLISTOCARDIOGRAM. II. NORMAL STANDARDS, ABNORMALITIES COMMONLY FOUND IN DISEASES OF THE HEART AND CIRCULATION, AND THEIR SIGNIFICANCE.

Authors:  I Starr; H A Schroeder
Journal:  J Clin Invest       Date:  1940-05       Impact factor: 14.808

4.  COMPARISON OF RESULTS OF THE NORMAL BALLISTOCARDIOGRAM AND A DIRECT FICK METHOD IN MEASURING THE CARDIAC OUTPUT IN MAN.

Authors:  A Cournand; H A Ranges; R L Riley
Journal:  J Clin Invest       Date:  1942-05       Impact factor: 14.808

5.  THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN.

Authors:  H W Smith; N Finkelstein; L Aliminosa; B Crawford; M Graber
Journal:  J Clin Invest       Date:  1945-05       Impact factor: 14.808

6.  THE CONTROL OF RENAL BLOOD FLOW AND GLOMERULAR FILTRATION IN NORMAL MAN.

Authors:  H Chasis; H A Ranges; W Goldring; H W Smith
Journal:  J Clin Invest       Date:  1938-09       Impact factor: 14.808

7.  VARIATIONS IN THE CARDIAC OUTPUT OF MAN: V. The Cardiac Output of Man During the Malaise and Pyrexia Following the Injection of Typhoid Vaccine.

Authors:  A Grollman
Journal:  J Clin Invest       Date:  1929-12       Impact factor: 14.808

  7 in total
  21 in total

1.  EFFECT OF DOPAMINE IN MAN: AUGMENTATION OF SODIUM EXCRETION, GLOMERULAR FILTRATION RATE, AND RENAL PLASMA FLOW.

Authors:  R H MCDONALD; L I GOLDBERG; J L MCNAY; E P TUTTLE
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

2.  Functional aspects of the differential diagnosis of renal disease.

Authors:  J BROD
Journal:  Postgrad Med J       Date:  1963-03       Impact factor: 2.401

3.  Cardiopulmonary consequences of pyrogen-induced hyperpyrexia in man.

Authors:  K M MOSER; R B PERRY; P C LUCHSINGER
Journal:  J Clin Invest       Date:  1963-05       Impact factor: 14.808

4.  [Toxicology of bacterial endotoxins].

Authors:  H GOEING
Journal:  Klin Wochenschr       Date:  1962-05-01

5.  Hypertension and the kidney. II. Experimental basis of renal hypertension.

Authors:  W S PEART
Journal:  Br Med J       Date:  1959-12-26

6.  The destruction of red cells by antibodies in man. II. Pyrogenic, leukocytic and dermal responses to immune hemolysis.

Authors:  J H JANDL; A S TOMLINSON
Journal:  J Clin Invest       Date:  1958-08       Impact factor: 14.808

7.  The urinary excretion of sodium and potassium during the pyrogenic reaction in man.

Authors:  W LATHEM
Journal:  J Clin Invest       Date:  1956-09       Impact factor: 14.808

8.  Studies on the circulatory changes in the dog produced by endotoxin from gram-negative microorganisms.

Authors:  L D MACLEAN; W W SPINK; M B VISSCHER; M H WEIL
Journal:  J Clin Invest       Date:  1956-11       Impact factor: 14.808

9.  The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients.

Authors:  W S TILLETT; A J JOHNSON; W R McCARTY
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

10.  Cardiovascular and renal adjustments to a hypotensive agent (l'hydrazinophthalazine: Ciba BA-5968: apresoline).

Authors:  E L WILKINSON; H BACKMAN; H H HECHT
Journal:  J Clin Invest       Date:  1952-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.